Bennett WM, moderator. Forum. Postgraduate Education Course. Renal Week 2005; November 8-13, 2005; Philadelphia, PA.

AE Proportion (%)*

Myopathy 12/872 (1.38)

Rhabdomyolysis 38/872 (4.36)

Renal failure 44/872 (5.05)*Rosuvastatin AEs divided by the total number of all serious and nonserious AEs from 1999 to 2004 for the six statin drugs in the marketplace

Adverse events for rosuvastatin

Statin Renal clearance (%)

Atorvastatin <2

Lovastatin 10

Simvastatin 13

Pravastatin 20

Cerivastatin 24

Rosuvastatin 28

Renal clearance of statins

Bennett WM, moderator. Forum. Postgraduate Education Course. Renal Week 2005; November 8-13, 2005; Philadelphia, PA.